Monoclonal antibodies (mAbs) originate from a single B lymphocyte clone and bind uniquely to one specific antigen epitope. The production of monoclonal antibodies happens in laboratories utilizing hybridoma technology or recombinant DNA technology. Monoclonal antibodies represent a critical component in cancer treatment as they function as modern targeted therapy. Monoclonal antibodies stem from a single clone of B cells and demonstrate high specificity to bind distinctive antigens on cancer cell membranes and deliver precise attacks. Characteristics of monoclonal antibodies:
Monoclonal antibodies represent a type of antibody that originates from one B cell lineage and targets a particular antigen with high precision. Monoclonal antibodies represent a standard treatment option within cancer therapy protocols. Specific monoclonal antibodies attach themselves to tumor cell antigens which blocks tumor cell growth. Tumor cells become targets of attack through various immune system components mobilized by monoclonal antibodies. The destruction of targeted cells is accomplished by antibody-dependent cell-mediated cytotoxicity (ADCC) or by complement-dependent cytolysis (CDC) systems. Monoclonal antibodies can exert anti-tumor effects through the following mechanisms:
Blocking Signal Pathways
Binding to cancer cell surface receptors (such as HER2, EGFR), blocking them from receiving growth signals, and inhibiting tumor proliferation.
Inducing Cytotoxic Reactions
CDC (complement-dependent cytotoxicity): Activating the complement system to attack cancer cells.
Directly Inducing Apoptosis
Some antibodies themselves can activate the apoptosis signaling pathway of cancer cells. "Delivery tool" function, bringing radioactive isotopes, cytotoxic drugs or immunotoxins to the tumor location and accurately releasing them.
Drug Name | Target | Indications |
---|---|---|
Trastuzumab | HER2 | HER2-positive breast cancer, gastric cancer |
Cetuximab | EGFR | Colorectal cancer, head and neck cancer |
Rituximab | CD20 | B-cell lymphoma, CLL |
Bevacizumab | VEGF | Colorectal cancer, lung cancer, kidney cancer, etc. |
Targeting Cancer Cell Surface Antigens
Monoclonal antibodies identify specific antigens on cancer cell surfaces like HER2, EGFR, CD20 to block growth signals that sustain cancer cells. Targeting cancer cells with monoclonal antibodies achieves immune system recognition while also triggering cancer cell apoptosis directly.
Delivering Toxins or Drugs
Monoclonal antibodies serve as precise delivery systems to transport toxins and chemotherapy drugs or radioactive substances directly to cancer cells through antibody-drug conjugate (ADC) treatment protocols.
Development Trends
Monoclonal antibodies represent a group of antibodies created by one kind of B cell which targets specific antigens with high precision. Monoclonal antibodies function as carriers to deliver anticancer drugs or radioactive substances directly to tumor cells which enhances treatment selectivity and effectiveness. Antibodies block tumor growth and spread by targeting signaling pathways like EGFR and VEGF which promote tumor development. Apatinib serves as a monoclonal antibody targeting VEGF for treatment of specific cancer types. Monoclonal antibodies like anti-PD-1 and anti-CTLA-4 boost the body's immune defenses against tumors by releasing the immune suppression that tumors create. Examples include pembrolizumab and ipilimumab.
The effectiveness of monoclonal antibodies in cancer treatment has been proven to be substantial and recent advances in biotechnology continue to allow for the development and implementation of new monoclonal antibodies. Some side effects including allergic reactions and immune system abnormalities can result from their use which requires careful evaluation during application.
Reference
Note: If you don't receive our verification email, do the following: